Hereditary Angioedema

Rare Disease·MeSH: Angioedemas, Hereditary

Prevalence

5.0 / 100K

22 drugs in development·10 companies·22 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
DAWNZERA™ (donidalorsen)	IONIS PHARMACEUTICALS INC (IONS)
ekterly	KalVista Pharmaceuticals, Inc. (KALV)
orladeyo	BIOCRYST PHARMACEUTICALS INC (BCRX)
Orladeyo	Royalty Pharma plc (RPRX)
ORLADEYO (berotralstat)	BIOCRYST PHARMACEUTICALS INC (BCRX)

Phase 3(10)

Drug	Company
Berotralstat	BIOCRYST PHARMACEUTICALS INC (BCRX)
deucrictibant	Pharvaris N.V. (PHVS)
drug	KalVista Pharmaceuticals, Inc. (KALV)
kvd900	KalVista Pharmaceuticals, Inc. (KALV)
navenibart	BIOCRYST PHARMACEUTICALS INC (BCRX)
navenibart	Astria Therapeutics, Inc. (ATXS)
NTLA-2002	Intellia Therapeutics, Inc. (NTLA)
ORLADEYO (berotralstat) oral granule formulation	BIOCRYST PHARMACEUTICALS INC (BCRX)
otl-105	Orchard Therapeutics plc (ORTX)
sebetralstat odt	KalVista Pharmaceuticals, Inc. (KALV)

Phase 2(1)

Drug	Company
donidalorsen	IONIS PHARMACEUTICALS INC (IONS)

Unknown(4)

Drug	Company
icatibant	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
icatibant	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
lanadelumab	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
lanadelumab	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 1/Phase 2(2)

Drug	Company
biological ntla-2002	Intellia Therapeutics, Inc. (NTLA)
STAR-0215	Astria Therapeutics, Inc. (ATXS)

BioSniper tracks 22 drugs in development for Hereditary Angioedema across 10 companies.

There are 22 clinical trials targeting Hereditary Angioedema tracked by BioSniper.

The estimated prevalence of Hereditary Angioedema is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.